| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatitis, Autoimmune | 24 | 2026 | 51 | 6.280 |
Why?
|
| Liver Cirrhosis, Biliary | 39 | 2026 | 90 | 5.640 |
Why?
|
| Hepacivirus | 42 | 2020 | 273 | 4.510 |
Why?
|
| Hepatitis C, Chronic | 33 | 2020 | 366 | 4.040 |
Why?
|
| Antiviral Agents | 41 | 2024 | 806 | 3.980 |
Why?
|
| Ribavirin | 30 | 2018 | 86 | 3.980 |
Why?
|
| Interferon-alpha | 26 | 2016 | 240 | 3.210 |
Why?
|
| Polyethylene Glycols | 23 | 2016 | 234 | 2.950 |
Why?
|
| Liver Transplantation | 53 | 2026 | 1132 | 2.770 |
Why?
|
| Proline | 15 | 2018 | 78 | 2.040 |
Why?
|
| Hepatitis B | 19 | 2024 | 172 | 1.960 |
Why?
|
| Hepatitis C | 16 | 2017 | 388 | 1.910 |
Why?
|
| Cholangitis, Sclerosing | 11 | 2025 | 74 | 1.890 |
Why?
|
| RNA, Viral | 26 | 2018 | 502 | 1.820 |
Why?
|
| Liver Cirrhosis | 20 | 2026 | 909 | 1.810 |
Why?
|
| Cholangitis | 14 | 2025 | 39 | 1.690 |
Why?
|
| PPAR delta | 6 | 2026 | 11 | 1.380 |
Why?
|
| Liver | 40 | 2026 | 1801 | 1.350 |
Why?
|
| Hepatic Encephalopathy | 9 | 2016 | 82 | 1.350 |
Why?
|
| Immunosuppressive Agents | 17 | 2024 | 659 | 1.340 |
Why?
|
| Chemical and Drug Induced Liver Injury | 10 | 2026 | 146 | 1.180 |
Why?
|
| Imidazoles | 11 | 2020 | 219 | 1.150 |
Why?
|
| Hepatitis B virus | 13 | 2024 | 137 | 1.150 |
Why?
|
| Quinoxalines | 10 | 2020 | 39 | 1.080 |
Why?
|
| Chenodeoxycholic Acid | 2 | 2024 | 19 | 0.910 |
Why?
|
| Drug Therapy, Combination | 29 | 2018 | 1164 | 0.900 |
Why?
|
| Terminology as Topic | 9 | 2015 | 225 | 0.900 |
Why?
|
| Humans | 201 | 2026 | 130357 | 0.860 |
Why?
|
| Tissue and Organ Procurement | 9 | 2021 | 253 | 0.840 |
Why?
|
| Hepatitis | 6 | 2022 | 57 | 0.830 |
Why?
|
| Ursodeoxycholic Acid | 12 | 2024 | 38 | 0.810 |
Why?
|
| Sulfonamides | 12 | 2020 | 294 | 0.800 |
Why?
|
| Recombinant Proteins | 25 | 2016 | 1323 | 0.800 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 3 | 2023 | 408 | 0.760 |
Why?
|
| Graft Rejection | 12 | 2026 | 556 | 0.760 |
Why?
|
| Middle Aged | 87 | 2026 | 28338 | 0.720 |
Why?
|
| Adult | 95 | 2026 | 31093 | 0.720 |
Why?
|
| Alkaline Phosphatase | 10 | 2026 | 95 | 0.710 |
Why?
|
| Tissue Donors | 9 | 2021 | 501 | 0.700 |
Why?
|
| Genotype | 25 | 2020 | 2606 | 0.700 |
Why?
|
| Viral Load | 13 | 2018 | 403 | 0.690 |
Why?
|
| Benzofurans | 5 | 2020 | 33 | 0.670 |
Why?
|
| Acetates | 6 | 2024 | 78 | 0.650 |
Why?
|
| Liver Failure, Acute | 3 | 2011 | 95 | 0.650 |
Why?
|
| Carbamates | 14 | 2020 | 63 | 0.640 |
Why?
|
| Meta-Analysis as Topic | 1 | 2020 | 169 | 0.620 |
Why?
|
| Aged | 53 | 2026 | 20854 | 0.580 |
Why?
|
| Bile Ducts | 5 | 2011 | 52 | 0.580 |
Why?
|
| Ammonia | 2 | 2015 | 68 | 0.570 |
Why?
|
| Polymerase Chain Reaction | 9 | 2013 | 1458 | 0.550 |
Why?
|
| Autoimmune Diseases | 6 | 2019 | 264 | 0.530 |
Why?
|
| Cystatin C | 1 | 2018 | 71 | 0.520 |
Why?
|
| Graft vs Host Disease | 8 | 2011 | 682 | 0.520 |
Why?
|
| Male | 96 | 2026 | 64493 | 0.510 |
Why?
|
| Double-Blind Method | 17 | 2024 | 1626 | 0.490 |
Why?
|
| Female | 96 | 2026 | 70272 | 0.490 |
Why?
|
| Cholagogues and Choleretics | 7 | 2024 | 24 | 0.490 |
Why?
|
| Renal Insufficiency | 1 | 2018 | 251 | 0.460 |
Why?
|
| DNA, Viral | 9 | 2015 | 452 | 0.450 |
Why?
|
| Glomerular Filtration Rate | 2 | 2018 | 568 | 0.450 |
Why?
|
| Automobile Driving | 1 | 2015 | 28 | 0.450 |
Why?
|
| Liability, Legal | 1 | 2015 | 49 | 0.440 |
Why?
|
| T-Lymphocytes, Regulatory | 3 | 2011 | 233 | 0.440 |
Why?
|
| Chalcones | 3 | 2026 | 6 | 0.440 |
Why?
|
| Propionates | 3 | 2026 | 31 | 0.430 |
Why?
|
| Autoantibodies | 10 | 2026 | 439 | 0.430 |
Why?
|
| Treatment Outcome | 35 | 2026 | 12854 | 0.430 |
Why?
|
| Cyclopropanes | 10 | 2020 | 67 | 0.430 |
Why?
|
| Virus Physiological Phenomena | 1 | 2014 | 12 | 0.410 |
Why?
|
| Drug Resistance, Viral | 7 | 2018 | 57 | 0.400 |
Why?
|
| Gastrointestinal Agents | 2 | 2024 | 63 | 0.400 |
Why?
|
| Liver Failure | 4 | 2017 | 99 | 0.380 |
Why?
|
| Allografts | 5 | 2026 | 218 | 0.370 |
Why?
|
| Thiazolidinediones | 1 | 2012 | 81 | 0.350 |
Why?
|
| Cognition Disorders | 1 | 2015 | 556 | 0.340 |
Why?
|
| Mass Screening | 5 | 2019 | 806 | 0.340 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2011 | 33 | 0.330 |
Why?
|
| Amides | 7 | 2020 | 82 | 0.330 |
Why?
|
| Young Adult | 22 | 2024 | 9970 | 0.330 |
Why?
|
| Biopsy | 10 | 2026 | 1237 | 0.330 |
Why?
|
| Severity of Illness Index | 7 | 2017 | 3030 | 0.330 |
Why?
|
| Autoantigens | 1 | 2011 | 99 | 0.320 |
Why?
|
| Lactams, Macrocyclic | 10 | 2020 | 33 | 0.320 |
Why?
|
| Sofosbuvir | 4 | 2018 | 20 | 0.310 |
Why?
|
| HIV | 1 | 2011 | 177 | 0.310 |
Why?
|
| Transplant Recipients | 3 | 2021 | 227 | 0.310 |
Why?
|
| Drug Overdose | 3 | 2020 | 70 | 0.300 |
Why?
|
| Epithelial Cells | 4 | 2011 | 895 | 0.300 |
Why?
|
| Interferons | 6 | 2014 | 136 | 0.290 |
Why?
|
| Community Health Services | 1 | 2010 | 87 | 0.290 |
Why?
|
| Hypertension, Portal | 4 | 2014 | 79 | 0.290 |
Why?
|
| Hepatitis B, Chronic | 2 | 2007 | 89 | 0.290 |
Why?
|
| Bile Ducts, Intrahepatic | 4 | 1993 | 103 | 0.290 |
Why?
|
| Physicians | 1 | 2015 | 634 | 0.280 |
Why?
|
| Viral Nonstructural Proteins | 5 | 2018 | 137 | 0.280 |
Why?
|
| Oligopeptides | 3 | 2014 | 105 | 0.280 |
Why?
|
| Risk Factors | 17 | 2025 | 10934 | 0.270 |
Why?
|
| Adolescent | 32 | 2023 | 20724 | 0.270 |
Why?
|
| Pruritus | 6 | 2024 | 49 | 0.270 |
Why?
|
| Thiazoles | 2 | 2026 | 111 | 0.260 |
Why?
|
| Immunoglobulins | 4 | 2005 | 155 | 0.260 |
Why?
|
| Insulin Resistance | 1 | 2012 | 683 | 0.260 |
Why?
|
| Bilirubin | 7 | 2026 | 126 | 0.250 |
Why?
|
| Liver Diseases | 8 | 2007 | 383 | 0.250 |
Why?
|
| Retrospective Studies | 25 | 2025 | 17633 | 0.240 |
Why?
|
| Clinical Trials as Topic | 5 | 2024 | 1125 | 0.240 |
Why?
|
| Interleukins | 5 | 2014 | 122 | 0.240 |
Why?
|
| Referral and Consultation | 1 | 2010 | 556 | 0.240 |
Why?
|
| Patient Selection | 3 | 2020 | 720 | 0.240 |
Why?
|
| Cyclosporine | 5 | 2016 | 130 | 0.230 |
Why?
|
| Biliary Tract Diseases | 2 | 1999 | 33 | 0.230 |
Why?
|
| Cholestasis | 3 | 2023 | 165 | 0.230 |
Why?
|
| Virus Activation | 4 | 2024 | 85 | 0.230 |
Why?
|
| Isoquinolines | 2 | 2015 | 43 | 0.220 |
Why?
|
| Survival Analysis | 3 | 2007 | 1499 | 0.220 |
Why?
|
| Biomarkers | 10 | 2023 | 3392 | 0.220 |
Why?
|
| PPAR alpha | 2 | 2023 | 53 | 0.220 |
Why?
|
| Hepatitis B Antibodies | 6 | 2012 | 24 | 0.210 |
Why?
|
| Pyrrolidines | 7 | 2018 | 46 | 0.210 |
Why?
|
| alpha 1-Antitrypsin Deficiency | 1 | 2024 | 43 | 0.210 |
Why?
|
| Pharmacovigilance | 1 | 2024 | 11 | 0.210 |
Why?
|
| Living Donors | 5 | 2021 | 112 | 0.210 |
Why?
|
| alpha 1-Antitrypsin | 1 | 2024 | 81 | 0.210 |
Why?
|
| Models, Statistical | 2 | 2017 | 482 | 0.210 |
Why?
|
| Peroxisome Proliferator-Activated Receptors | 1 | 2023 | 10 | 0.210 |
Why?
|
| HIV Infections | 3 | 2018 | 2012 | 0.200 |
Why?
|
| Iron Overload | 1 | 2023 | 18 | 0.200 |
Why?
|
| Prognosis | 10 | 2020 | 4900 | 0.200 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2024 | 59 | 0.200 |
Why?
|
| Hemochromatosis | 1 | 2023 | 39 | 0.200 |
Why?
|
| T-Lymphocytes | 9 | 2012 | 1711 | 0.200 |
Why?
|
| Hepatitis B Surface Antigens | 7 | 2012 | 59 | 0.190 |
Why?
|
| Hepatitis B Antigens | 4 | 2010 | 10 | 0.190 |
Why?
|
| Deoxycytidine | 2 | 2013 | 81 | 0.190 |
Why?
|
| Transaminases | 3 | 2022 | 37 | 0.190 |
Why?
|
| Liver Neoplasms | 7 | 2014 | 1395 | 0.190 |
Why?
|
| Antibodies, Antinuclear | 2 | 2019 | 31 | 0.190 |
Why?
|
| Sex Factors | 2 | 2018 | 1332 | 0.190 |
Why?
|
| Immunization | 2 | 2024 | 265 | 0.190 |
Why?
|
| Disease Susceptibility | 3 | 2020 | 279 | 0.190 |
Why?
|
| Drug Administration Schedule | 7 | 2018 | 729 | 0.190 |
Why?
|
| Recurrence | 9 | 2018 | 1475 | 0.180 |
Why?
|
| Graft Survival | 6 | 2021 | 461 | 0.180 |
Why?
|
| Data Collection | 1 | 2024 | 366 | 0.180 |
Why?
|
| Plasma Cells | 1 | 2022 | 54 | 0.180 |
Why?
|
| Elasticity Imaging Techniques | 2 | 2021 | 153 | 0.180 |
Why?
|
| Treatment Failure | 4 | 2018 | 351 | 0.180 |
Why?
|
| Disease Progression | 6 | 2022 | 2204 | 0.180 |
Why?
|
| Kidney Transplantation | 3 | 2020 | 562 | 0.180 |
Why?
|
| Valine | 6 | 2018 | 109 | 0.170 |
Why?
|
| Clinical Trials, Phase III as Topic | 3 | 2018 | 75 | 0.170 |
Why?
|
| Donor Selection | 2 | 2019 | 58 | 0.170 |
Why?
|
| Gilbert Disease | 4 | 2013 | 4 | 0.170 |
Why?
|
| Gene Expression Regulation, Viral | 2 | 1992 | 126 | 0.170 |
Why?
|
| Antineoplastic Agents | 3 | 2019 | 1792 | 0.170 |
Why?
|
| HLA Antigens | 4 | 2016 | 225 | 0.170 |
Why?
|
| Transplantation, Homologous | 6 | 2007 | 669 | 0.170 |
Why?
|
| Mice, Inbred BALB C | 6 | 2011 | 973 | 0.160 |
Why?
|
| Immunotherapy | 2 | 2005 | 752 | 0.160 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 2 | 2017 | 31 | 0.160 |
Why?
|
| Fibrosis | 1 | 2022 | 419 | 0.160 |
Why?
|
| Neoplasms | 7 | 2020 | 2942 | 0.160 |
Why?
|
| Cystic Fibrosis | 3 | 2020 | 266 | 0.160 |
Why?
|
| Tacrolimus | 5 | 2021 | 102 | 0.160 |
Why?
|
| Follow-Up Studies | 9 | 2025 | 5190 | 0.160 |
Why?
|
| Waiting Lists | 4 | 2020 | 242 | 0.160 |
Why?
|
| Risk Assessment | 4 | 2018 | 3684 | 0.160 |
Why?
|
| Benzimidazoles | 2 | 2018 | 155 | 0.160 |
Why?
|
| Learning Curve | 1 | 2020 | 54 | 0.150 |
Why?
|
| Transplantation | 1 | 2019 | 25 | 0.150 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2024 | 836 | 0.150 |
Why?
|
| Health Facilities | 1 | 2019 | 66 | 0.150 |
Why?
|
| Drug Combinations | 5 | 2018 | 273 | 0.150 |
Why?
|
| Chronic Disease | 9 | 2026 | 1231 | 0.150 |
Why?
|
| Protease Inhibitors | 3 | 2017 | 95 | 0.140 |
Why?
|
| Administration, Oral | 5 | 2024 | 695 | 0.140 |
Why?
|
| Leukocytes, Mononuclear | 2 | 1991 | 355 | 0.140 |
Why?
|
| Inflammation | 2 | 2022 | 1474 | 0.140 |
Why?
|
| Diagnosis, Differential | 4 | 2026 | 1891 | 0.140 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2014 | 783 | 0.140 |
Why?
|
| Vaccination | 1 | 2024 | 1040 | 0.140 |
Why?
|
| Nucleoside-Triphosphatase | 3 | 2015 | 21 | 0.140 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2025 | 750 | 0.140 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2013 | 298 | 0.140 |
Why?
|
| Immunization, Passive | 4 | 2000 | 122 | 0.140 |
Why?
|
| Organ Transplantation | 1 | 2020 | 168 | 0.140 |
Why?
|
| Spleen | 4 | 2011 | 257 | 0.140 |
Why?
|
| Survival Rate | 4 | 2019 | 2132 | 0.130 |
Why?
|
| Uridine | 1 | 2017 | 31 | 0.130 |
Why?
|
| Carcinoma, Hepatocellular | 4 | 2014 | 1005 | 0.130 |
Why?
|
| Sustained Virologic Response | 4 | 2018 | 47 | 0.130 |
Why?
|
| Animals | 26 | 2024 | 33909 | 0.130 |
Why?
|
| Macrocyclic Compounds | 1 | 2017 | 13 | 0.130 |
Why?
|
| Suicide | 1 | 2020 | 198 | 0.130 |
Why?
|
| Pancreatic Neoplasms | 1 | 2023 | 742 | 0.130 |
Why?
|
| Hepatitis, Viral, Human | 2 | 1994 | 43 | 0.130 |
Why?
|
| Narcotics | 1 | 2017 | 59 | 0.130 |
Why?
|
| Glycerol | 2 | 2014 | 78 | 0.130 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2024 | 1613 | 0.130 |
Why?
|
| Biological Products | 1 | 2019 | 141 | 0.130 |
Why?
|
| Serine Endopeptidases | 3 | 2015 | 196 | 0.130 |
Why?
|
| Phenylbutyrates | 2 | 2014 | 55 | 0.120 |
Why?
|
| DEAD-box RNA Helicases | 3 | 2015 | 159 | 0.120 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 313 | 0.120 |
Why?
|
| Triazoles | 1 | 2017 | 138 | 0.120 |
Why?
|
| Acetaminophen | 2 | 2013 | 97 | 0.120 |
Why?
|
| Adenocarcinoma | 1 | 2023 | 987 | 0.120 |
Why?
|
| Prevalence | 2 | 2022 | 2682 | 0.120 |
Why?
|
| Creatinine | 1 | 2018 | 397 | 0.120 |
Why?
|
| Hypertension, Pulmonary | 2 | 2014 | 450 | 0.120 |
Why?
|
| Incidence | 3 | 2025 | 3329 | 0.120 |
Why?
|
| Bile Duct Diseases | 2 | 1993 | 16 | 0.120 |
Why?
|
| Immunologic Factors | 2 | 2020 | 187 | 0.120 |
Why?
|
| Fasting | 2 | 2015 | 304 | 0.120 |
Why?
|
| Glutamine | 2 | 2014 | 204 | 0.110 |
Why?
|
| Hepatitis B Core Antigens | 3 | 2012 | 14 | 0.110 |
Why?
|
| Mandatory Reporting | 1 | 2015 | 20 | 0.110 |
Why?
|
| Histocytochemistry | 1 | 2015 | 83 | 0.110 |
Why?
|
| Neoplasms, Vascular Tissue | 1 | 1995 | 3 | 0.110 |
Why?
|
| Lung Transplantation | 1 | 2020 | 353 | 0.110 |
Why?
|
| Decision Support Techniques | 1 | 2018 | 296 | 0.110 |
Why?
|
| Geography | 1 | 2015 | 116 | 0.110 |
Why?
|
| Quality of Life | 6 | 2021 | 2070 | 0.110 |
Why?
|
| Benzazepines | 1 | 2015 | 43 | 0.110 |
Why?
|
| Cytokines | 4 | 2011 | 1335 | 0.110 |
Why?
|
| Drugs, Chinese Herbal | 1 | 1994 | 20 | 0.110 |
Why?
|
| Accidents, Traffic | 1 | 2015 | 103 | 0.110 |
Why?
|
| Inflammation Mediators | 2 | 2019 | 228 | 0.110 |
Why?
|
| Lactams | 1 | 2014 | 22 | 0.110 |
Why?
|
| Confidentiality | 1 | 2015 | 105 | 0.110 |
Why?
|
| Congresses as Topic | 3 | 2023 | 185 | 0.110 |
Why?
|
| Ritonavir | 1 | 2014 | 44 | 0.110 |
Why?
|
| Secondary Prevention | 4 | 2000 | 219 | 0.110 |
Why?
|
| Thioguanine | 2 | 2004 | 21 | 0.100 |
Why?
|
| Viral Hepatitis Vaccines | 1 | 2014 | 19 | 0.100 |
Why?
|
| Therapies, Investigational | 1 | 2014 | 13 | 0.100 |
Why?
|
| Aged, 80 and over | 8 | 2021 | 6760 | 0.100 |
Why?
|
| Acute Disease | 4 | 2025 | 1151 | 0.100 |
Why?
|
| Indoles | 1 | 2015 | 199 | 0.100 |
Why?
|
| Cell Movement | 2 | 2005 | 871 | 0.100 |
Why?
|
| Cancer Care Facilities | 1 | 2013 | 32 | 0.100 |
Why?
|
| Hyperammonemia | 1 | 2014 | 59 | 0.100 |
Why?
|
| Phenylacetates | 1 | 2013 | 27 | 0.100 |
Why?
|
| Metabolomics | 1 | 2017 | 503 | 0.100 |
Why?
|
| Autoimmunity | 2 | 2024 | 175 | 0.100 |
Why?
|
| Caffeine | 1 | 2013 | 66 | 0.100 |
Why?
|
| Liver Function Tests | 6 | 2020 | 98 | 0.100 |
Why?
|
| Minor Histocompatibility Loci | 2 | 1991 | 2 | 0.100 |
Why?
|
| Uridine Monophosphate | 1 | 2013 | 8 | 0.100 |
Why?
|
| DNA-Directed RNA Polymerases | 1 | 1993 | 77 | 0.100 |
Why?
|
| Sensitivity and Specificity | 4 | 2007 | 2111 | 0.100 |
Why?
|
| Azathioprine | 3 | 2018 | 37 | 0.100 |
Why?
|
| Limit of Detection | 1 | 2013 | 73 | 0.100 |
Why?
|
| Time Factors | 11 | 2019 | 6186 | 0.100 |
Why?
|
| Pandemics | 1 | 2020 | 1153 | 0.100 |
Why?
|
| Liver, Artificial | 2 | 2011 | 9 | 0.100 |
Why?
|
| Medical Futility | 1 | 2013 | 40 | 0.100 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2014 | 193 | 0.090 |
Why?
|
| Pharmacogenetics | 1 | 2014 | 203 | 0.090 |
Why?
|
| Urea Cycle Disorders, Inborn | 1 | 2013 | 84 | 0.090 |
Why?
|
| RNA Probes | 1 | 1992 | 27 | 0.090 |
Why?
|
| United States | 11 | 2017 | 11813 | 0.090 |
Why?
|
| Child | 14 | 2021 | 26152 | 0.090 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2014 | 323 | 0.090 |
Why?
|
| Lymphocyte Activation | 3 | 2011 | 630 | 0.090 |
Why?
|
| Aspirin | 1 | 2013 | 215 | 0.090 |
Why?
|
| Lamivudine | 2 | 2002 | 29 | 0.090 |
Why?
|
| Receptors, Cell Surface | 2 | 1984 | 420 | 0.090 |
Why?
|
| Logistic Models | 2 | 2014 | 1800 | 0.090 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2012 | 60 | 0.090 |
Why?
|
| Length of Stay | 1 | 2017 | 1393 | 0.090 |
Why?
|
| Mice | 10 | 2011 | 18203 | 0.090 |
Why?
|
| Cell Adhesion Molecules | 1 | 1992 | 225 | 0.090 |
Why?
|
| Cyclophilins | 1 | 2011 | 19 | 0.090 |
Why?
|
| Amino Acid Substitution | 1 | 2013 | 407 | 0.090 |
Why?
|
| Contraindications | 2 | 2006 | 76 | 0.090 |
Why?
|
| Hepatitis C Antibodies | 2 | 2010 | 26 | 0.090 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2013 | 157 | 0.090 |
Why?
|
| Rituximab | 3 | 2020 | 170 | 0.090 |
Why?
|
| Hodgkin Disease | 1 | 1994 | 307 | 0.090 |
Why?
|
| Self Tolerance | 1 | 2011 | 4 | 0.090 |
Why?
|
| RNA, Messenger | 3 | 2012 | 2567 | 0.090 |
Why?
|
| Base Sequence | 5 | 1998 | 2767 | 0.080 |
Why?
|
| Kidney | 1 | 2017 | 1283 | 0.080 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 2011 | 39 | 0.080 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2011 | 60 | 0.080 |
Why?
|
| Rats | 7 | 2008 | 3400 | 0.080 |
Why?
|
| Cell Line, Transformed | 1 | 2011 | 160 | 0.080 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 528 | 0.080 |
Why?
|
| Immune Tolerance | 2 | 2007 | 154 | 0.080 |
Why?
|
| Molecular Sequence Data | 5 | 1998 | 3507 | 0.080 |
Why?
|
| Cholestasis, Intrahepatic | 2 | 2008 | 58 | 0.080 |
Why?
|
| Chemokines | 1 | 2011 | 124 | 0.080 |
Why?
|
| Predictive Value of Tests | 2 | 2018 | 2298 | 0.080 |
Why?
|
| Viral Structural Proteins | 1 | 1990 | 39 | 0.080 |
Why?
|
| Bone Marrow Transplantation | 2 | 2011 | 590 | 0.080 |
Why?
|
| Budesonide | 2 | 2016 | 17 | 0.080 |
Why?
|
| Genes, Viral | 1 | 1990 | 155 | 0.080 |
Why?
|
| Crohn Disease | 2 | 2004 | 291 | 0.080 |
Why?
|
| Disease Models, Animal | 4 | 2011 | 4660 | 0.080 |
Why?
|
| Algorithms | 3 | 2026 | 1680 | 0.080 |
Why?
|
| Copper | 2 | 1981 | 70 | 0.080 |
Why?
|
| Mycophenolic Acid | 2 | 2016 | 62 | 0.080 |
Why?
|
| Inflammatory Bowel Diseases | 2 | 2004 | 326 | 0.080 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 3 | 2013 | 265 | 0.080 |
Why?
|
| Remission Induction | 4 | 2018 | 299 | 0.080 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2011 | 256 | 0.080 |
Why?
|
| Lipopolysaccharides | 1 | 2011 | 300 | 0.070 |
Why?
|
| Colitis, Ulcerative | 1 | 2011 | 215 | 0.070 |
Why?
|
| Trans-Activators | 1 | 1992 | 705 | 0.070 |
Why?
|
| B-Lymphocytes | 1 | 2012 | 509 | 0.070 |
Why?
|
| Age Factors | 1 | 2015 | 2834 | 0.070 |
Why?
|
| Hospitalization | 1 | 2017 | 1927 | 0.070 |
Why?
|
| Interferon-gamma | 3 | 1999 | 545 | 0.070 |
Why?
|
| Hyaluronan Receptors | 1 | 2008 | 64 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 1215 | 0.070 |
Why?
|
| Hypoglycemic Agents | 1 | 2012 | 479 | 0.070 |
Why?
|
| Dendritic Cells | 1 | 2011 | 435 | 0.070 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2018 | 85 | 0.070 |
Why?
|
| Aminoisobutyric Acids | 2 | 2018 | 7 | 0.070 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2011 | 463 | 0.070 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2011 | 498 | 0.070 |
Why?
|
| Cytotoxicity, Immunologic | 3 | 1981 | 272 | 0.070 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2011 | 1004 | 0.070 |
Why?
|
| United Kingdom | 2 | 2019 | 254 | 0.070 |
Why?
|
| Chylous Ascites | 1 | 1987 | 10 | 0.070 |
Why?
|
| Evidence-Based Medicine | 1 | 2011 | 645 | 0.070 |
Why?
|
| Texas | 2 | 2021 | 3614 | 0.070 |
Why?
|
| Hyperbilirubinemia, Hereditary | 3 | 1982 | 3 | 0.070 |
Why?
|
| Insemination, Artificial, Heterologous | 1 | 1987 | 2 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2024 | 3407 | 0.060 |
Why?
|
| Hyaluronic Acid | 1 | 2008 | 108 | 0.060 |
Why?
|
| Insemination, Artificial | 1 | 1987 | 11 | 0.060 |
Why?
|
| Lymphatic Diseases | 1 | 1987 | 28 | 0.060 |
Why?
|
| Prednisolone | 2 | 2018 | 70 | 0.060 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 1994 | 849 | 0.060 |
Why?
|
| Policy Making | 1 | 2007 | 59 | 0.060 |
Why?
|
| Macrophages | 1 | 1991 | 654 | 0.060 |
Why?
|
| Abdomen | 1 | 1987 | 129 | 0.060 |
Why?
|
| Mitogens | 3 | 1992 | 30 | 0.060 |
Why?
|
| Leucine | 2 | 2018 | 259 | 0.060 |
Why?
|
| Epoprostenol | 1 | 2006 | 35 | 0.060 |
Why?
|
| Immunity, Cellular | 2 | 2005 | 191 | 0.060 |
Why?
|
| Intercellular Adhesion Molecule-1 | 2 | 1999 | 122 | 0.060 |
Why?
|
| Cell Separation | 3 | 1992 | 220 | 0.060 |
Why?
|
| Cells, Cultured | 4 | 1999 | 2905 | 0.060 |
Why?
|
| Skin Diseases | 1 | 1987 | 141 | 0.060 |
Why?
|
| Activities of Daily Living | 1 | 2007 | 377 | 0.060 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2005 | 39 | 0.060 |
Why?
|
| Puerto Rico | 2 | 2016 | 49 | 0.060 |
Why?
|
| Risk Management | 1 | 2005 | 65 | 0.060 |
Why?
|
| Immunity, Innate | 1 | 2007 | 405 | 0.060 |
Why?
|
| Oxidation-Reduction | 2 | 2005 | 434 | 0.050 |
Why?
|
| Focal Nodular Hyperplasia | 1 | 2004 | 6 | 0.050 |
Why?
|
| Disease Management | 2 | 2020 | 559 | 0.050 |
Why?
|
| Prospective Studies | 3 | 2022 | 6417 | 0.050 |
Why?
|
| 1-Naphthylisothiocyanate | 1 | 2004 | 2 | 0.050 |
Why?
|
| Hepatectomy | 1 | 2005 | 125 | 0.050 |
Why?
|
| RNAi Therapeutics | 1 | 2024 | 17 | 0.050 |
Why?
|
| Coinfection | 2 | 2018 | 187 | 0.050 |
Why?
|
| Nausea | 2 | 2017 | 83 | 0.050 |
Why?
|
| Microscopy, Electron | 4 | 2004 | 310 | 0.050 |
Why?
|
| Chemokines, CXC | 1 | 2004 | 36 | 0.050 |
Why?
|
| Liver Diseases, Alcoholic | 2 | 1997 | 61 | 0.050 |
Why?
|
| Retreatment | 2 | 2016 | 87 | 0.050 |
Why?
|
| Hepatitis A | 2 | 2013 | 28 | 0.050 |
Why?
|
| Drug Carriers | 2 | 2015 | 116 | 0.050 |
Why?
|
| Transferrins | 1 | 2023 | 2 | 0.050 |
Why?
|
| Muromonab-CD3 | 1 | 2003 | 7 | 0.050 |
Why?
|
| Hemochromatosis Protein | 1 | 2023 | 22 | 0.050 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2005 | 225 | 0.050 |
Why?
|
| Fatty Liver | 1 | 2006 | 221 | 0.050 |
Why?
|
| Gene Expression Profiling | 1 | 2011 | 1827 | 0.050 |
Why?
|
| Hepcidins | 1 | 2023 | 26 | 0.050 |
Why?
|
| Nitrofurantoin | 1 | 2023 | 10 | 0.050 |
Why?
|
| Ferritins | 1 | 2023 | 108 | 0.050 |
Why?
|
| Antihypertensive Agents | 1 | 2006 | 420 | 0.050 |
Why?
|
| Benzothiazoles | 1 | 2023 | 31 | 0.050 |
Why?
|
| Isoxazoles | 1 | 2023 | 32 | 0.050 |
Why?
|
| Postoperative Complications | 4 | 2020 | 3105 | 0.050 |
Why?
|
| Piperazines | 1 | 2005 | 269 | 0.050 |
Why?
|
| Hepatopulmonary Syndrome | 1 | 2002 | 8 | 0.050 |
Why?
|
| Dysbiosis | 1 | 2024 | 145 | 0.050 |
Why?
|
| In Vitro Techniques | 3 | 1992 | 809 | 0.050 |
Why?
|
| Enzyme Inhibitors | 1 | 2005 | 568 | 0.050 |
Why?
|
| Hyperlipidemias | 1 | 2004 | 188 | 0.050 |
Why?
|
| Models, Theoretical | 3 | 2019 | 363 | 0.050 |
Why?
|
| Sirolimus | 1 | 2004 | 229 | 0.050 |
Why?
|
| Gene Expression Regulation | 1 | 2011 | 2356 | 0.050 |
Why?
|
| Cholic Acids | 1 | 1982 | 16 | 0.050 |
Why?
|
| Ceruloplasmin | 2 | 1981 | 13 | 0.050 |
Why?
|
| Cloning, Molecular | 2 | 1994 | 782 | 0.050 |
Why?
|
| RNA, Small Interfering | 1 | 2024 | 666 | 0.050 |
Why?
|
| Child, Preschool | 6 | 2011 | 14976 | 0.050 |
Why?
|
| Cell Proliferation | 2 | 2008 | 2472 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2005 | 1233 | 0.040 |
Why?
|
| Granuloma, Plasma Cell | 1 | 2001 | 4 | 0.040 |
Why?
|
| Gastroenterology | 1 | 2005 | 221 | 0.040 |
Why?
|
| Adjuvants, Immunologic | 1 | 2003 | 391 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2012 | 1426 | 0.040 |
Why?
|
| Major Histocompatibility Complex | 2 | 1992 | 49 | 0.040 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2002 | 146 | 0.040 |
Why?
|
| Bile Acids and Salts | 1 | 2024 | 259 | 0.040 |
Why?
|
| Pyrimidines | 1 | 2005 | 452 | 0.040 |
Why?
|
| Transplantation, Heterologous | 2 | 2000 | 257 | 0.040 |
Why?
|
| gamma-Glutamyltransferase | 1 | 2021 | 49 | 0.040 |
Why?
|
| Infant | 5 | 2011 | 13277 | 0.040 |
Why?
|
| Cohort Studies | 4 | 2014 | 5073 | 0.040 |
Why?
|
| T-Lymphocyte Subsets | 2 | 1992 | 197 | 0.040 |
Why?
|
| Cross-Sectional Studies | 1 | 2010 | 3799 | 0.040 |
Why?
|
| Isoantigens | 2 | 1992 | 23 | 0.040 |
Why?
|
| History, 21st Century | 2 | 2015 | 256 | 0.040 |
Why?
|
| Lymphocytes | 3 | 1980 | 348 | 0.040 |
Why?
|
| Monocytes | 3 | 1992 | 336 | 0.040 |
Why?
|
| Iron | 1 | 2023 | 305 | 0.040 |
Why?
|
| History, 20th Century | 2 | 2015 | 360 | 0.040 |
Why?
|
| Hepatitis Antigens | 1 | 2000 | 1 | 0.040 |
Why?
|
| Cyclophosphamide | 1 | 2002 | 436 | 0.040 |
Why?
|
| Methotrexate | 1 | 2002 | 337 | 0.040 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2018 | 331 | 0.040 |
Why?
|
| B7-1 Antigen | 1 | 1999 | 12 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 2 | 2019 | 543 | 0.040 |
Why?
|
| Histocompatibility Antigens | 1 | 1999 | 16 | 0.040 |
Why?
|
| Epidemics | 1 | 2020 | 57 | 0.040 |
Why?
|
| Carbonic Anhydrases | 1 | 1999 | 21 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2018 | 2923 | 0.040 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2006 | 770 | 0.040 |
Why?
|
| Hepatitis B Vaccines | 1 | 2000 | 49 | 0.040 |
Why?
|
| Transfection | 2 | 1992 | 962 | 0.040 |
Why?
|
| Abatacept | 1 | 2019 | 22 | 0.040 |
Why?
|
| Asialoglycoprotein Receptor | 3 | 1984 | 5 | 0.040 |
Why?
|
| Cell Transformation, Viral | 1 | 1999 | 96 | 0.040 |
Why?
|
| Epithelium | 2 | 1993 | 339 | 0.040 |
Why?
|
| Decision Trees | 1 | 2019 | 57 | 0.040 |
Why?
|
| Orosomucoid | 1 | 1978 | 9 | 0.040 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2020 | 216 | 0.040 |
Why?
|
| Simian virus 40 | 1 | 1999 | 190 | 0.040 |
Why?
|
| Aneurysm, Infected | 1 | 1998 | 23 | 0.040 |
Why?
|
| Drug Monitoring | 1 | 2021 | 286 | 0.040 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2019 | 124 | 0.040 |
Why?
|
| Molecular Mimicry | 1 | 2018 | 17 | 0.030 |
Why?
|
| Radioisotopes | 1 | 1978 | 26 | 0.030 |
Why?
|
| Bacterial Infections | 1 | 2001 | 322 | 0.030 |
Why?
|
| Fatal Outcome | 2 | 1998 | 362 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2011 | 8525 | 0.030 |
Why?
|
| SEER Program | 1 | 2019 | 211 | 0.030 |
Why?
|
| Hepatolenticular Degeneration | 1 | 1978 | 36 | 0.030 |
Why?
|
| Postoperative Care | 1 | 2000 | 296 | 0.030 |
Why?
|
| Patient Outcome Assessment | 1 | 2018 | 90 | 0.030 |
Why?
|
| Benzopyrans | 1 | 2017 | 18 | 0.030 |
Why?
|
| Medicaid | 1 | 2000 | 250 | 0.030 |
Why?
|
| Alanine Transaminase | 1 | 2017 | 157 | 0.030 |
Why?
|
| Attitude to Health | 1 | 1998 | 244 | 0.030 |
Why?
|
| Taiwan | 1 | 2016 | 65 | 0.030 |
Why?
|
| Portasystemic Shunt, Transjugular Intrahepatic | 1 | 1996 | 16 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2019 | 379 | 0.030 |
Why?
|
| Leukocyte Count | 2 | 2004 | 249 | 0.030 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 1998 | 225 | 0.030 |
Why?
|
| Cause of Death | 1 | 2019 | 503 | 0.030 |
Why?
|
| Asia | 1 | 2016 | 125 | 0.030 |
Why?
|
| Medicare | 1 | 2000 | 438 | 0.030 |
Why?
|
| Japan | 1 | 2016 | 166 | 0.030 |
Why?
|
| Methyltransferases | 1 | 2016 | 78 | 0.030 |
Why?
|
| Hepatitis, Chronic | 1 | 1995 | 3 | 0.030 |
Why?
|
| Rifamycins | 1 | 2016 | 18 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2016 | 277 | 0.030 |
Why?
|
| Immunoglobulin G | 2 | 2018 | 790 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 1999 | 1607 | 0.030 |
Why?
|
| Diarrhea | 1 | 2017 | 311 | 0.030 |
Why?
|
| History, 19th Century | 1 | 2015 | 111 | 0.030 |
Why?
|
| Hemangioendothelioma, Epithelioid | 1 | 1995 | 10 | 0.030 |
Why?
|
| Hepatitis B e Antigens | 2 | 2002 | 14 | 0.030 |
Why?
|
| End Stage Liver Disease | 1 | 2017 | 191 | 0.030 |
Why?
|
| Portal Vein | 1 | 1995 | 88 | 0.030 |
Why?
|
| Isoindoles | 1 | 2014 | 4 | 0.030 |
Why?
|
| Nutrition Surveys | 2 | 2007 | 326 | 0.030 |
Why?
|
| Hepatitis D | 1 | 1994 | 3 | 0.030 |
Why?
|
| Hepatitis Delta Virus | 1 | 1994 | 6 | 0.030 |
Why?
|
| Hepatitis E virus | 1 | 1994 | 5 | 0.030 |
Why?
|
| International Classification of Diseases | 1 | 2015 | 98 | 0.030 |
Why?
|
| Cytochrome P-450 CYP3A Inhibitors | 1 | 2014 | 10 | 0.030 |
Why?
|
| Hepatovirus | 1 | 1994 | 9 | 0.030 |
Why?
|
| Magnetic Resonance Angiography | 1 | 1995 | 165 | 0.030 |
Why?
|
| Hepatitis E | 1 | 1994 | 7 | 0.030 |
Why?
|
| Hemangiosarcoma | 1 | 1995 | 47 | 0.030 |
Why?
|
| Ligases | 1 | 1994 | 35 | 0.030 |
Why?
|
| Kidney Failure, Chronic | 1 | 2002 | 941 | 0.030 |
Why?
|
| Quality Control | 1 | 1994 | 115 | 0.030 |
Why?
|
| Medication Adherence | 1 | 2018 | 332 | 0.030 |
Why?
|
| Rats, Inbred Strains | 2 | 1984 | 185 | 0.030 |
Why?
|
| Molecular Biology | 1 | 1994 | 66 | 0.030 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1994 | 297 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2017 | 517 | 0.030 |
Why?
|
| Gene Amplification | 1 | 1994 | 222 | 0.030 |
Why?
|
| Antigens, Viral | 1 | 1995 | 392 | 0.030 |
Why?
|
| Mitochondria | 1 | 1999 | 764 | 0.030 |
Why?
|
| Taq Polymerase | 1 | 1993 | 7 | 0.030 |
Why?
|
| Preoperative Care | 2 | 2006 | 356 | 0.030 |
Why?
|
| Magnesium Chloride | 1 | 1993 | 3 | 0.030 |
Why?
|
| RNA-Directed DNA Polymerase | 1 | 1993 | 37 | 0.030 |
Why?
|
| Administration, Inhalation | 1 | 2014 | 192 | 0.030 |
Why?
|
| Patient Preference | 1 | 2015 | 149 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2014 | 167 | 0.030 |
Why?
|
| Polycystic Kidney Diseases | 1 | 1993 | 31 | 0.030 |
Why?
|
| Decision Making | 1 | 2019 | 687 | 0.030 |
Why?
|
| Oligonucleotide Probes | 1 | 1993 | 85 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2018 | 1221 | 0.020 |
Why?
|
| Osmolar Concentration | 1 | 1993 | 147 | 0.020 |
Why?
|
| Arterial Pressure | 1 | 2014 | 131 | 0.020 |
Why?
|
| Urea | 1 | 2014 | 218 | 0.020 |
Why?
|
| Proteins | 1 | 1978 | 1015 | 0.020 |
Why?
|
| Bile | 2 | 2004 | 44 | 0.020 |
Why?
|
| DNA-Directed DNA Polymerase | 1 | 1993 | 86 | 0.020 |
Why?
|
| Necrosis | 1 | 1993 | 195 | 0.020 |
Why?
|
| Viral Regulatory and Accessory Proteins | 1 | 1992 | 37 | 0.020 |
Why?
|
| Vasodilator Agents | 1 | 2014 | 197 | 0.020 |
Why?
|
| Virus Replication | 1 | 1995 | 597 | 0.020 |
Why?
|
| Substance-Related Disorders | 1 | 1997 | 480 | 0.020 |
Why?
|
| Canada | 1 | 2013 | 321 | 0.020 |
Why?
|
| Suppressor Factors, Immunologic | 1 | 1992 | 2 | 0.020 |
Why?
|
| Antibodies | 2 | 1992 | 320 | 0.020 |
Why?
|
| Blotting, Northern | 1 | 1992 | 236 | 0.020 |
Why?
|
| Placebos | 1 | 2012 | 225 | 0.020 |
Why?
|
| Genes | 1 | 1992 | 310 | 0.020 |
Why?
|
| Indomethacin | 1 | 1992 | 78 | 0.020 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 1992 | 70 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2012 | 228 | 0.020 |
Why?
|
| Introns | 1 | 1992 | 281 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2014 | 1077 | 0.020 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 1992 | 110 | 0.020 |
Why?
|
| Lymphocytes, Null | 1 | 1991 | 2 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 1992 | 985 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 2012 | 330 | 0.020 |
Why?
|
| Plastics | 1 | 1991 | 13 | 0.020 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 1991 | 92 | 0.020 |
Why?
|
| Viral Proteins | 1 | 1992 | 339 | 0.020 |
Why?
|
| Pulmonary Artery | 1 | 2014 | 437 | 0.020 |
Why?
|
| Cell Membrane | 3 | 1984 | 451 | 0.020 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2013 | 292 | 0.020 |
Why?
|
| Cell Division | 1 | 1992 | 721 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 1991 | 263 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2014 | 1398 | 0.020 |
Why?
|
| Ischemia | 1 | 1993 | 354 | 0.020 |
Why?
|
| Sarcoidosis | 1 | 1990 | 52 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2002 | 4671 | 0.020 |
Why?
|
| Antigen-Presenting Cells | 1 | 1990 | 122 | 0.020 |
Why?
|
| Autoradiography | 1 | 1989 | 63 | 0.020 |
Why?
|
| Laparoscopy | 1 | 1995 | 540 | 0.020 |
Why?
|
| Case-Control Studies | 2 | 2007 | 3387 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1990 | 413 | 0.020 |
Why?
|
| Fatigue | 1 | 2010 | 195 | 0.020 |
Why?
|
| Indocyanine Green | 2 | 1982 | 51 | 0.020 |
Why?
|
| Genetic Diseases, Inborn | 1 | 1993 | 470 | 0.020 |
Why?
|
| Organ Specificity | 1 | 1989 | 397 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2013 | 1250 | 0.020 |
Why?
|
| Rats, Inbred F344 | 1 | 2008 | 98 | 0.020 |
Why?
|
| Ligation | 1 | 2008 | 133 | 0.020 |
Why?
|
| Epitopes | 1 | 1989 | 322 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 1992 | 1391 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 1990 | 767 | 0.020 |
Why?
|
| Databases as Topic | 1 | 2007 | 74 | 0.020 |
Why?
|
| Peritoneum | 1 | 1987 | 36 | 0.020 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 1990 | 232 | 0.020 |
Why?
|
| Anemia | 1 | 2011 | 351 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1995 | 2109 | 0.020 |
Why?
|
| Eligibility Determination | 1 | 2007 | 36 | 0.020 |
Why?
|
| Hyperoxaluria, Primary | 1 | 2006 | 13 | 0.020 |
Why?
|
| Resource Allocation | 1 | 2007 | 52 | 0.020 |
Why?
|
| Government Regulation | 1 | 2007 | 43 | 0.020 |
Why?
|
| Semen | 1 | 1987 | 84 | 0.020 |
Why?
|
| Kupffer Cells | 2 | 1984 | 20 | 0.020 |
Why?
|
| Social Justice | 1 | 2007 | 65 | 0.020 |
Why?
|
| Ascites | 1 | 2006 | 98 | 0.020 |
Why?
|
| Spectrophotometry, Atomic | 1 | 1985 | 5 | 0.010 |
Why?
|
| Bile Canaliculi | 1 | 1985 | 4 | 0.010 |
Why?
|
| Basement Membrane | 1 | 1985 | 40 | 0.010 |
Why?
|
| Microvilli | 1 | 1985 | 63 | 0.010 |
Why?
|
| Fibroblasts | 1 | 1990 | 857 | 0.010 |
Why?
|
| California | 1 | 2006 | 127 | 0.010 |
Why?
|
| Reproductive Medicine | 1 | 2005 | 17 | 0.010 |
Why?
|
| Surveys and Questionnaires | 2 | 2006 | 3997 | 0.010 |
Why?
|
| Cell Line | 1 | 1990 | 2577 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 1987 | 360 | 0.010 |
Why?
|
| Bile Duct Neoplasms | 1 | 2006 | 128 | 0.010 |
Why?
|
| Anthropometry | 1 | 2005 | 187 | 0.010 |
Why?
|
| Pilot Projects | 2 | 2002 | 1451 | 0.010 |
Why?
|
| Imatinib Mesylate | 1 | 2005 | 47 | 0.010 |
Why?
|
| Medical Records | 1 | 2005 | 177 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2006 | 544 | 0.010 |
Why?
|
| Demography | 1 | 2005 | 238 | 0.010 |
Why?
|
| Sulfobromophthalein | 2 | 1982 | 3 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2006 | 561 | 0.010 |
Why?
|
| Hydroxyproline | 1 | 2004 | 7 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 1984 | 236 | 0.010 |
Why?
|
| Benzamides | 1 | 2005 | 125 | 0.010 |
Why?
|
| Golgi Apparatus | 1 | 1984 | 93 | 0.010 |
Why?
|
| Immune Sera | 1 | 1984 | 55 | 0.010 |
Why?
|
| Mutation | 1 | 1998 | 6131 | 0.010 |
Why?
|
| Rabbits | 3 | 1980 | 574 | 0.010 |
Why?
|
| Interviews as Topic | 1 | 2005 | 441 | 0.010 |
Why?
|
| Endothelium | 1 | 1984 | 61 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 1984 | 164 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2007 | 1378 | 0.010 |
Why?
|
| Endoplasmic Reticulum | 1 | 1984 | 210 | 0.010 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 1984 | 136 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2006 | 814 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 1995 | 3841 | 0.010 |
Why?
|
| Hyperplasia | 1 | 2003 | 190 | 0.010 |
Why?
|
| Pulmonary Diffusing Capacity | 1 | 2002 | 8 | 0.010 |
Why?
|
| Hepatitis Antibodies | 1 | 2002 | 5 | 0.010 |
Why?
|
| Mononuclear Phagocyte System | 2 | 1981 | 9 | 0.010 |
Why?
|
| Carrier Proteins | 2 | 1985 | 1006 | 0.010 |
Why?
|
| Life Style | 1 | 2005 | 444 | 0.010 |
Why?
|
| Lysosomes | 1 | 1984 | 269 | 0.010 |
Why?
|
| Kinetics | 2 | 1982 | 1087 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 1982 | 83 | 0.010 |
Why?
|
| Drug Interactions | 1 | 1983 | 235 | 0.010 |
Why?
|
| Penicillamine | 1 | 1981 | 5 | 0.010 |
Why?
|
| Neutrophils | 1 | 2004 | 358 | 0.010 |
Why?
|
| Mesalamine | 1 | 2001 | 6 | 0.010 |
Why?
|
| Models, Biological | 1 | 2006 | 1390 | 0.010 |
Why?
|
| Spherocytosis, Hereditary | 1 | 1981 | 6 | 0.010 |
Why?
|
| Thyroxine | 1 | 1981 | 59 | 0.010 |
Why?
|
| Intestinal Absorption | 1 | 1981 | 170 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 1981 | 364 | 0.010 |
Why?
|
| Splenectomy | 1 | 1981 | 62 | 0.010 |
Why?
|
| Drug Prescriptions | 1 | 1983 | 229 | 0.010 |
Why?
|
| Peritoneal Dialysis | 1 | 2002 | 132 | 0.010 |
Why?
|
| Reference Values | 1 | 1982 | 679 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2006 | 1337 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2006 | 1292 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2006 | 1675 | 0.010 |
Why?
|
| Estrogens | 1 | 1981 | 430 | 0.010 |
Why?
|
| Receptors, Drug | 1 | 1979 | 27 | 0.010 |
Why?
|
| Complement C3b | 1 | 1978 | 7 | 0.010 |
Why?
|
| Animal Rights | 1 | 1998 | 1 | 0.010 |
Why?
|
| Hepatic Artery | 1 | 1998 | 45 | 0.010 |
Why?
|
| Intestinal Fistula | 1 | 1998 | 22 | 0.010 |
Why?
|
| Haplorhini | 1 | 1998 | 105 | 0.010 |
Why?
|
| Surface Properties | 1 | 1978 | 80 | 0.010 |
Why?
|
| Vascular Fistula | 1 | 1998 | 27 | 0.010 |
Why?
|
| Ileal Diseases | 1 | 1998 | 27 | 0.010 |
Why?
|
| Prednisone | 1 | 1999 | 238 | 0.010 |
Why?
|
| Drug Resistance | 1 | 1999 | 247 | 0.010 |
Why?
|
| Aorta, Abdominal | 1 | 1998 | 95 | 0.010 |
Why?
|
| Immunosorbent Techniques | 1 | 1977 | 15 | 0.010 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 1977 | 18 | 0.010 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 1977 | 19 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 1978 | 238 | 0.010 |
Why?
|
| Sarcoma, Experimental | 1 | 1977 | 15 | 0.010 |
Why?
|
| Trypsin | 1 | 1977 | 68 | 0.010 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 1977 | 28 | 0.010 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 1977 | 31 | 0.010 |
Why?
|
| Personality Inventory | 1 | 1998 | 175 | 0.010 |
Why?
|
| Temperance | 1 | 1997 | 15 | 0.010 |
Why?
|
| Homeostasis | 1 | 1981 | 715 | 0.010 |
Why?
|
| Dogs | 1 | 1998 | 614 | 0.010 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 1998 | 228 | 0.010 |
Why?
|
| Echocardiography | 1 | 2002 | 1124 | 0.010 |
Why?
|
| Consciousness | 1 | 1997 | 56 | 0.010 |
Why?
|
| Glucocorticoids | 1 | 1999 | 343 | 0.010 |
Why?
|
| Eosinophils | 1 | 1997 | 116 | 0.010 |
Why?
|
| Actuarial Analysis | 1 | 1996 | 27 | 0.010 |
Why?
|
| Aortic Diseases | 1 | 1998 | 188 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2004 | 3816 | 0.010 |
Why?
|
| Testosterone | 1 | 1981 | 590 | 0.010 |
Why?
|
| Thrombophlebitis | 1 | 1995 | 19 | 0.010 |
Why?
|
| Intracranial Pressure | 1 | 1997 | 218 | 0.010 |
Why?
|
| Ethics, Medical | 1 | 1998 | 398 | 0.010 |
Why?
|
| Equipment Design | 1 | 1997 | 541 | 0.010 |
Why?
|
| Diet | 1 | 1981 | 1097 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 1995 | 427 | 0.010 |
Why?
|
| Alcoholism | 1 | 1997 | 244 | 0.010 |
Why?
|
| Alcohol Drinking | 1 | 1997 | 343 | 0.010 |
Why?
|
| Protein Binding | 1 | 1978 | 1666 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 1998 | 2409 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 1995 | 938 | 0.010 |
Why?
|
| Swine | 1 | 1997 | 1184 | 0.010 |
Why?
|
| Radiography | 1 | 1995 | 750 | 0.010 |
Why?
|
| Hemodynamics | 1 | 1997 | 802 | 0.010 |
Why?
|
| Comorbidity | 1 | 1997 | 1587 | 0.010 |
Why?
|
| Biological Transport | 2 | 1979 | 332 | 0.000 |
Why?
|
| Hypersensitivity, Delayed | 1 | 1981 | 28 | 0.000 |
Why?
|
| Antigen-Antibody Complex | 1 | 1981 | 52 | 0.000 |
Why?
|
| Mitochondria, Liver | 1 | 1981 | 37 | 0.000 |
Why?
|
| Complement System Proteins | 1 | 1981 | 58 | 0.000 |
Why?
|
| Antigens | 1 | 1981 | 104 | 0.000 |
Why?
|
| Antigens, Surface | 1 | 1981 | 112 | 0.000 |
Why?
|
| Chromium Radioisotopes | 1 | 1980 | 2 | 0.000 |
Why?
|
| Antibody Formation | 1 | 1981 | 227 | 0.000 |
Why?
|
| Receptors, Fc | 1 | 1980 | 29 | 0.000 |
Why?
|
| Binding Sites, Antibody | 1 | 1980 | 44 | 0.000 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 1980 | 59 | 0.000 |
Why?
|
| Galactose | 1 | 1980 | 53 | 0.000 |
Why?
|
| Receptors, Complement | 1 | 1980 | 31 | 0.000 |
Why?
|
| Neuraminidase | 1 | 1980 | 40 | 0.000 |
Why?
|
| Killer Cells, Natural | 1 | 1981 | 342 | 0.000 |
Why?
|
| Receptor, Insulin | 1 | 1979 | 63 | 0.000 |
Why?
|
| Metabolic Clearance Rate | 1 | 1978 | 132 | 0.000 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 1978 | 40 | 0.000 |
Why?
|
| Glucagon | 1 | 1979 | 146 | 0.000 |
Why?
|
| Hematinics | 1 | 1979 | 60 | 0.000 |
Why?
|
| Lipoproteins | 1 | 1979 | 182 | 0.000 |
Why?
|
| Glycoproteins | 1 | 1979 | 346 | 0.000 |
Why?
|
| Binding Sites | 1 | 1978 | 1150 | 0.000 |
Why?
|
| Glucuronosyltransferase | 1 | 1976 | 63 | 0.000 |
Why?
|